Aurentz Vincent 4
4 · Inhibikase Therapeutics, Inc. · Filed Feb 24, 2026
Insider Transaction Report
Form 4
Aurentz Vincent
Director
Transactions
- Disposition to Issuer
Common Stock
[F1]2026-02-21−255,299→ 510,596 total
Footnotes (1)
- [F1]As previously reported on a Form 3/A filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the "Closing Date"), with 255,299 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 255,299 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.
Signature
/s/ Mark Iwicki, attorney-in-fact|2026-02-24